Study to Assess the Effectiveness of a Omega-3 Enriched Supplement on Chemotherapy Tolerance in Colon Cancer Patients
Study to Assess the Effectiveness of a Omega-3 Enriched Supplement on Chemotherapy Tolerance in Colon Cancer Patients
The purpose of this study is to determine if a nutritional supplement enriched in omega-3
 fatty acids is effective in improving the tolerance to chemotherapy treatment and improves
 quality of life.
Colorectal cancer is one of the main causes of mortality in western countries. It is
 considered that in case of colorectal carcinoma, the frequency of weight loss at the moment
 of diagnosis is 54%. Undernourishment affects negatively the course of the illness and it
 confers a worse prognostic, increasing the morbidity and the mortality, while it entails an
 impairment in the quality of life of the patient.

 There is a narrow relationship in the oncologic pathology between undernourishment and the
 pathology itself, drawing a common syndrome called cancerous cachexia. It is usual that
 patients subjected to chemotherapy present nutritional alterations due to the treatments'
 side effects.

 With this study we want to assess the efficacy of a nutritional intervention with
 supplementation enriched in EPA to improve the tolerance to the antineoplastic treatment. As
 an index of tolerability to the chemotherapy treatment, it will be used the variation of
 changes in quality of life evaluated through the questionnaire EORTC QLQ-C30, using the
 parameters of global quality of life and physical function.
Inclusion Criteria:

 -  Patients diagnosed of metastatic colon adenocarcinoma that are going to receive first
 line chemotherapy treatment in the oncology day hospital.

 -  Age over 18 years old.

 Exclusion Criteria:

 -  Patients diagnosed of colon cancer are receiving second line chemotherapy.

 -  Antecedents of other malignant tumors with the exception of basocellular epithelioma.

 -  Chronic renal failure (Creatinine > 1.7).

 -  Previous diabetes mellitus.

 -  Obesity (IMC > 30)

 -  Medical conditions that imply hepatic encephalopathy, or ascites.

 -  Severe malnutrition according to the classification of the Subjective Global
 Assessment (SGA) or a BMI < 16.5.

 -  Major psychiatric disorder.

 -  Patients receiving enteral or parenteral nutrition.

 -  Contraindications for the indication of the nutritional supplement: Galactosemia.

 -  Seafood or seafood byproducts allergy.

 -  Patients taking drugs that affect the metabolism (anabolic steroids, orexigenic
 agents...).

 -  Absence of the informed consent form signed by the patient.

 -  Any patient who has disability to comply with the treatment or who has inability
 according to the researcher.